2.78% -0.105

アフターアワーズ： 3.67

Lantern Pharma Inc (LTRN)

Lantern Pharma Inc (LTRN) 最新ニュース

Lantern Pharma Inc (LTRN)

Lantern Pharma Inc (LTRN) 最新ニュース

Lantern Pharma secures three new FDA rare disease tags - Investing.com

Lantern Pharma secures three new FDA rare disease tags - Investing.com India

Lantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184 - MarketWatch

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers - Business Wire

Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance

LTRN (Lantern Pharma) EPS (Basic) : $-1.65 (TTM As of Jun. 2024) - GuruFocus.com

Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Update - Defense World

LTRN (Lantern Pharma) 50-Day SMA : $4.42 (As of Aug. 17, 2024) - GuruFocus.com

LTRN (Lantern Pharma) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com

Q3 2024 Earnings Forecast for Lantern Pharma Inc. (NASDAQ:LTRN) Issued By Zacks Small Cap - Defense World

LTRN: Second Quarter Results - Yahoo Finance

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript - Seeking Alpha

LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024 - MSN

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates - StockTitan

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates - Business Wire

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 - Business Wire

Lantern Pharma (LTRN) Scheduled to Post Quarterly Earnings on Thursday - Defense World

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 - Yahoo Finance

LTRN: Harmonic Clinical Update - Zacks Small Cap Research

LTRN: Harmonic Clinical Update - Yahoo Finance

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort - Chronicle-Tribune

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort - StockTitan

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort - Business Wire

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET - Business Wire

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET - StockTitan

Head-To-Head Analysis: Lantern Pharma (NASDAQ:LTRN) versus CASI Pharmaceuticals (NASDAQ:CASI) - Defense World

CASI Pharmaceuticals (NASDAQ:CASI) versus Lantern Pharma (NASDAQ:LTRN) Financial Comparison - American Banking and Market News

CASI Pharmaceuticals (NASDAQ:CASI) versus Lantern Pharma (NASDAQ:LTRN) Financial Comparison - Defense World

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 - Marketscreener.com

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate - Yahoo Finance

Kintara Therapeutics restructures share designations By Investing.com - Investing.com

Cosmos Health completes hydrogel development for weight management By Investing.com - Investing.com India

Netflix shares price target lifted on Q2 earnings report - Investing.com

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 - Business Wire

LP-184 synergizes with PARP inhibitor in atypical teratoid rhabdoid tumor - BioWorld Online

How AI is transforming drug discovery - The Pharmaceutical Journal

Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Down 20.6% in June - MarketBeat

Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90 ... - The Globe and Mail

Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational Research Environment for Oncology ... - The Globe and Mail

Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical ... - Quantisnow

Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - The Globe and Mail

Lantern Pharma Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - The Globe and Mail

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 - The Globe and Mail

Lantern Pharma Inc (LTRN-Q) QuotePress Release - The Globe and Mail

, aids in the discovery of DNA damaging agent for the ultra-rare cancer Atypical Teratoid Rhabdoid Tumors - Frontiers

Ratios in Focus: Analyzing Lantern Pharma Inc (LTRN)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex

H.C. Wainwright initates Lantern Pharma Inc (LTRN) rating to a Buy – Knox Daily - Knox Daily

(LTRN) Trading Signals - Stock Traders Daily

How Much Are Lantern Pharma Inc. (NASDAQ:LTRN) Insiders Spending On Buying Shares? - Yahoo New Zealand News

Lantern Pharma secures Japan patent for cancer drug By Investing.com - Investing.com Australia

Lantern Pharma secures Japan patent for cancer drug By Investing.com - Investing.com

Lantern Pharma secures Japan patent for cancer drug By Investing.com - Investing.com UK

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering ... - Business Wire

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284 - Business Wire

Analytical Lens: Exploring Lantern Pharma Inc (LTRN)'s Financial Story Through Ratios – DWinneX - The Dwinnex

Lantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Aaron G.L. Fletcher Sells 10000 Shares - Defense World

Lantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Sells $62,500.00 in Stock - MarketBeat

Biotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024 - Baystreet.ca

(LTRN) Trading Report - Stock Traders Daily

LTRN: Expanding Horizons into Asia - Zacks Small Cap Research

LTRN: Expanding Horizons into Asia - Yahoo Finance

Lantern Pharma (LTRN) Stock Forecast and Price Target 2024 - MarketBeat

LTRNに似た銘柄